about
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national surveyClinical outcomes in psoriatic arthritis: A systematic literature reviewAnti-Interleukin-1 Agents in Adult Onset Still's DiseaseReal time identification of drug-induced liver injury (DILI) through daily screening of ALT results: a prospective pilot cohort studyTapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.Prediction of Remission in a French Early Arthritis Cohort by RAPID3 and other Core Data Set Measures, but Not by the Absence of Rheumatoid Factor, Anticitrullinated Protein Antibodies, or Radiographic Erosions.Performance of matrices developed to identify patients with early rheumatoid arthritis with rapid radiographic progression despite methotrexate therapy: an external validation study based on the ESPOIR cohort data.Early non-response to certolizumab pegol in rheumatoid arthritis predicts treatment failure at one year. Data from a randomised phase III clinical trial.Baseline laboratory test abnormalities are common in early arthritis but rarely contraindicate methotrexate: study of three cohorts (ESPOIR, VErA, and Brittany).Benefits of ultrasonography in the management of early arthritis: a cross-sectional study of baseline data from the ESPOIR cohort.Use of glucocorticoids in rheumatoid arthritis - pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion.Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation--an economic analysis based on the ESPOIR cohort.Indications of glucocorticoids in early arthritis and rheumatoid arthritis: recommendations for clinical practice based on data from the literature and expert opinion.The gap between practice and guidelines in the choice of first-line disease modifying antirheumatic drug in early rheumatoid arthritis: results from the ESPOIR cohort.Long-term return to work after a functional restoration program for chronic low-back pain patients: a prospective studyLevel of agreement of the 1987 ACR and 2010 ACR/EULAR rheumatoid arthritis classification criteria: an analysis based on ESPOIR cohort data.Effect of adherence to European treatment recommendations on early arthritis outcome: data from the ESPOIR cohort.Cost effectiveness of therapeutic interventions in ankylosing spondylitis: a critical and systematic review.Cost of illness studies in rheumatic diseases.Therapeutic vaccination with TNF-Kinoid in TNF antagonist-resistant rheumatoid arthritis: a phase II randomized, controlled clinical trialFive-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.Recommendations for the prevention of osteoporosis and fragility fractures. International comparison and synthesis.Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.Reappraisal of the diagnostic and prognostic value of morning stiffness in arthralgia and early arthritis: results from the Groningen EARC, Leiden EARC, ESPOIR, Leiden EAC and REACH.Response to 'Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis'.Relationship between optimism and quality of life in patients with two chronic rheumatic diseases: axial spondyloarthritis and chronic low back pain: a cross sectional study of 288 patients.Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA).Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion.Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion.Adult Onset Still's Disease and Autoinflammation.Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy.Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohortIncidence and prevalence of systemic sclerosis: a systematic literature review.Matrix to predict rapid radiographic progression of early rheumatoid arthritis patients from the community treated with methotrexate or leflunomide: results from the ESPOIR cohort.Adult-onset Still disease.Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients.Abatacept therapy and safety management.Multireader assessment as an alternative to reference assessment to improve the detection of radiographic progression in a large longitudinal cohort of rheumatoid arthritis (ESPOIR).Infections induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review.Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review.
P50
Q24816756-5DFD4733-57BF-4BF0-BDAB-03F8A7D08401Q26995307-E1A38E8B-1CEE-4702-8D91-53F9876F66A4Q27495968-7F2E919E-EFAA-4475-B563-DA7058623EC7Q28482250-7D1600BF-9BB7-47CE-BD57-4B08E6DD38F8Q30249836-E98D770B-56A1-4E44-A50E-A49C350D48C8Q31078892-1A862E88-3990-4D2C-BB29-53A0A75FCC55Q31104875-FFE9692D-E125-4A76-BC9C-9BCB3CA43805Q31163470-6D6976AD-1945-4392-8A8F-A7160653A93FQ33405505-7EE13AD7-482A-43FC-AB33-00B68C018DFBQ33503502-BB91DAD5-6030-4B44-BC30-87E4AECA4ED8Q33578743-087EE8E5-DE02-4C52-AE5A-ABBF7DB6CD98Q33584199-0E387050-E27D-4477-BEFB-C6E883F3C776Q33623141-7F171DE7-973F-4920-8D58-3D2EC3416E08Q33772793-4DF0CC7C-2242-4493-BCBE-7BBF8A6484FAQ33974917-A0B563E7-F3D1-4E67-93B2-358BFE6838FCQ34062037-79B09CFE-8BB4-4CED-9D7B-F87BE4EBB31DQ34259444-6B5C7361-861A-453B-80E0-9A0DECEE9CB9Q34457872-6E04C36B-0F52-4FA1-8852-7C3B04C1FCD2Q34531177-4870C8DF-5D95-408C-A264-6A71EC3673DAQ34724711-E7DA6128-451C-4500-8FEF-A4B165C5C64BQ34945123-25293C07-34AB-4CDB-A164-5E634F003EE5Q34976559-0678B132-1CF1-4CDD-A7CB-0313F957A363Q35122583-DDCB6DB9-C089-45DF-9C66-B1F64EFE00EDQ35654047-A26C0D20-14BC-4CEA-B04A-8144710D1D7DQ35762424-9BDEAAE2-68FF-40CA-BD0B-7E5778A488AAQ35819270-E7E467F1-7A27-43BE-BBA9-044471F3DE0EQ36005210-A975CC13-CC8A-4FA6-984B-D164E4E56893Q36083502-780E61F7-3BFD-4853-9A0F-5A9CB5FC6CF9Q36105879-0257E79D-E8F4-4D65-9ED0-3A5361A9D008Q36220940-991CC21F-39EA-4F3A-829F-1E4D4D928855Q36694682-FC661C47-94F7-44AF-B14F-34D77FED5D88Q36773679-3496AD0A-B49B-4BDC-A4CC-BA3A1AB19A77Q36907677-694D7B5B-3310-4270-BEA9-F9F8BC0739B6Q36907694-B3589AC2-1691-4986-9058-607333B2FCDAQ37333091-71B43D2E-C92E-40B6-B218-C53578CE52E5Q37453985-96C08BAB-1564-4EEB-B229-1EF21F9F85D6Q37533319-4100A8A8-C895-41E8-A33B-93E55B6840D0Q37587397-168940D9-057F-4F17-BEF3-474DC1817BA0Q37745531-EFD271EE-A434-4CF5-AB76-4821FB7D921EQ37753155-6F78E78E-2A03-4EBD-B945-828D3076763A
P50
description
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Bruno Fautrel
@ast
Bruno Fautrel
@en
Bruno Fautrel
@es
Bruno Fautrel
@nl
type
label
Bruno Fautrel
@ast
Bruno Fautrel
@en
Bruno Fautrel
@es
Bruno Fautrel
@nl
prefLabel
Bruno Fautrel
@ast
Bruno Fautrel
@en
Bruno Fautrel
@es
Bruno Fautrel
@nl
P214
P106
P1960
8H8ZZw8AAAAJ
P21
P214
P31
P735
P7859
viaf-194876487